Guru Fundamental Report for HIMS

Validea's guru fundamental report indicates that HIMS & HERS HEALTH INC (HIMS) receives a 75% rating based on their Small-Cap Growth Investor model, which is based on the published strategy of Motley Fool. The rating is driven by strong fundamentals and price performance, with the stock passing key criteria such as profit margin, relative strength, and insider holdings; however, it fails in areas like cash and cash equivalents, the Fool Ratio, and sales, indicating mixed signals for investors following this particular strategy.

Analysis

HIMS & HERS HEALTH INC (HIMS), a large-cap growth stock in the Biotechnology & Drugs industry, received a 75% rating from Validea's Small-Cap Growth Investor model, which is based on the Motley Fool's published strategy. This score is below the 80% threshold that typically indicates the strategy has 'some interest' and significantly below the 90% mark for 'strong interest'. While HIMS passed several fundamental criteria, including profit margin, relative strength, sales and EPS growth compared to the same period last year, insider holdings, cash flow from operations, profit margin consistency, R&D as a percentage of sales, inventory to sales, accounts receivable to sales, long-term debt/equity ratio, and price, it failed on several critical metrics. Notably, HIMS did not meet the criteria for cash and cash equivalents, 'The Fool Ratio' (P/E to Growth), average shares outstanding, sales, daily dollar volume, and income tax percentage. The failure on 'sales' and 'The Fool Ratio' raises concerns about top-line growth momentum and valuation relative to growth, respectively, while the 'cash and cash equivalents' and 'daily dollar volume' failures point to potential liquidity and market interest issues. Despite a mildly positive sentiment score for the article (0.15) and a HIMS-specific sentiment of 0.4, the quantitative model's sub-threshold score and specific metric failures present a mixed picture.

Key Decisions for Investors

• Investors should exercise caution due to HIMS's 75% score on the Validea Small-Cap Growth model, which falls below the typical threshold for 'some interest' according to the strategy's interpretation.
• A thorough due diligence is warranted, focusing on the reasons for failure in key areas such as cash and cash equivalents, sales performance, the P/E to growth (Fool Ratio), daily dollar volume, and average shares outstanding, as these could indicate underlying financial or valuation concerns.
• While the stock passes several fundamental and price performance tests, the significance of the failed criteria, particularly for a growth-oriented company, should be carefully weighed against these positive aspects before making investment decisions based on this specific model.